Last updated on July 2017

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy


Brief description of study

The purpose of this study is to evaluate the tolerability, safety and the pharmacokinetic (PK) profile of daratumumab in Chinese participants with relapsed or refractory multiple myeloma (RRMM) who failed at least 2 prior lines of systemic therapy (Part 1 and Part 2); and to evaluate the tolerability and safety of daratumumab in Chinese participants whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) and who have demonstrated disease progression on the last therapy (Part 3).

Clinical Study Identifier: NCT02852837

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Peking University Third Hospital

Peking University Third Hospital
Beijing, China
  Connect »

First Affiliated Hospital, Medical School ...

First Affiliated Hospital, Medical School of Zhejiang University
Hangzhou, China
  Connect »

Ruijin Hospital, Shanghai Jiao Tong ...

Ruijin Hospital, Shanghai Jiao Tong University
Shanghai, China
  Connect »

Institute of Hematology & Blood ...

Institute of Hematology & Blood Diseases Hospital
Tianjin, China, China
  Connect »